Coverage, Coding and Reasonable Payment for HIV-1 and Resistance Testing
Guidance for : This letter provides information about two relatively new laboratory tests for the management of Human Immunodeficiency Virus (HIV) disease to assist State Medicaid agencies in establishing policies regarding coverage, coding, and reasonable payment for these tests. The two tests are genotype human immunodeficiency virus type-1 (HIV-1) testing (mutation analysis) for drug resistance and phenotype HIV-1 drug susceptibility (commonly referred to as resistance) testing.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: January 08, 2001
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.